Bal­loon­ing 340B mar­ket reach­es al­most 15% of 2021 US phar­ma sales, IQVIA finds

The tale of a boom­ing fed­er­al drug dis­count pro­gram, which phar­ma com­pa­nies have sought to cur­tail, has of­ten been told but rarely with new num­bers.

Now, the drug pric­ing gu­rus at IQVIA say their lat­est da­ta shows that the pro­gram, known as 340B and once de­signed to give mas­sive dis­counts to on­ly a se­lect num­ber of out­pa­tient drugs for on­ly a se­lect few health care providers, has bal­looned to $93.6 bil­lion in sales in 2021, which is about 15% of the to­tal $668.3 bil­lion in phar­ma sales for the year.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Life Sciences Senior Associate

General Catalyst

San Francisco, CA, USA